Comparison of Resistance Spectra after First and Second Line Osimertinib Treatment Detected by Liquid Biopsy

Comparison of Resistance Spectra after First and Second Line Osimertinib Treatment Detected by Liquid Biopsy

Since 2009, several first, second, and third generation <i>EGFR</i> tyrosine kinase inhibitors (TKI) have been approved for targeted treatment of <i>EGFR</i> mutated metastatic non-small lung cancer (NSCLC). A vast majority of patients is improving quickly on treatment; howev...

Full description

Bibliographic Details
Main Authors: Balázs Jóri, Stefanie Schatz, Len Kaller, Bettina Kah, Julia Roeper, Hayat O. Ramdani, Linda Diehl, Petra Hoffknecht, Christian Grohé, Frank Griesinger, Markus Tiemann, Lukas C. Heukamp, Markus Falk
Format: Article
Language:English
Published: MDPI AG 2021-06-01
Series:Cancers
Subjects:
liquid biopsy
lung cancer
routine diagnostics
osimertinib resistance
Online Access:https://www.mdpi.com/2072-6694/13/12/2861

Internet

https://www.mdpi.com/2072-6694/13/12/2861

Similar Items